$2.57T
Total marketcap
$177.62B
Total volume
BTC 49.93%     ETH 15.86%
Dominance

PTC Therapeutics PTCT Stock

29.01 USD {{ price }} -1.827408% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
2.22B USD
LOW - HIGH [24H]
28.57 - 29.84 USD
VOLUME [24H]
526.44K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-8.37 USD

PTC Therapeutics Price Chart

PTC Therapeutics PTCT Financial and Trading Overview

PTC Therapeutics stock price 29.01 USD
Previous Close 43.01 USD
Open 42.79 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 42.49 - 44.01 USD
52 Week Range 27.09 - 59.84 USD
Volume 479.57K USD
Avg. Volume 857.19K USD
Market Cap 3.23B USD
Beta (5Y Monthly) 0.421126
PE Ratio (TTM) N/A
EPS (TTM) -8.37 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 52.93 USD

PTCT Valuation Measures

Enterprise Value 4.4B USD
Trailing P/E N/A
Forward P/E -13.939104
PEG Ratio (5 yr expected) 1.08
Price/Sales (ttm) 4.187893
Price/Book (mrq) N/A
Enterprise Value/Revenue 5.717
Enterprise Value/EBITDA -14.072

Trading Information

PTC Therapeutics Stock Price History

Beta (5Y Monthly) 0.421126
52-Week Change 53.07%
S&P500 52-Week Change 20.43%
52 Week High 59.84 USD
52 Week Low 27.09 USD
50-Day Moving Average 50.45 USD
200-Day Moving Average 46.28 USD

PTCT Share Statistics

Avg. Volume (3 month) 857.19K USD
Avg. Daily Volume (10-Days) 626.7K USD
Shares Outstanding 74.19M
Float 65.32M
Short Ratio 5.89
% Held by Insiders 2.60%
% Held by Institutions 106.44%
Shares Short 6.34M
Short % of Float 11.65%
Short % of Shares Outstanding 8.55%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -74.14%
Operating Margin (ttm) -59.49%
Gross Margin 1.78%
EBITDA Margin -40.62%

Management Effectiveness

Return on Assets (ttm) -16.80%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 770.45M USD
Revenue Per Share (ttm) 10.65 USD
Quarterly Revenue Growth (yoy) 48.19%
Gross Profit (ttm) 2.63M USD
EBITDA -313028000 USD
Net Income Avi to Common (ttm) -571249984 USD
Diluted EPS (ttm) -7.78
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 286.3M USD
Total Cash Per Share (mrq) 3.86 USD
Total Debt (mrq) 1.46B USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 1.389
Book Value Per Share (mrq) -6.182

Cash Flow Statement

Operating Cash Flow (ttm) -288740992 USD
Levered Free Cash Flow (ttm) -257165872 USD

Profile of PTC Therapeutics

Country United States
State NJ
City South Plainfield
Address 100 Corporate Court
ZIP 07080
Phone 908 222 7000
Website https://www.ptcbio.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1402

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Q&A For PTC Therapeutics Stock

What is a current PTCT stock price?

PTC Therapeutics PTCT stock price today per share is 29.01 USD.

How to purchase PTC Therapeutics stock?

You can buy PTCT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for PTC Therapeutics?

The stock symbol or ticker of PTC Therapeutics is PTCT.

Which industry does the PTC Therapeutics company belong to?

The PTC Therapeutics industry is Biotechnology.

How many shares does PTC Therapeutics have in circulation?

The max supply of PTC Therapeutics shares is 76.61M.

What is PTC Therapeutics Price to Earnings Ratio (PE Ratio)?

PTC Therapeutics PE Ratio is now.

What was PTC Therapeutics earnings per share over the trailing 12 months (TTM)?

PTC Therapeutics EPS is -8.37 USD over the trailing 12 months.

Which sector does the PTC Therapeutics company belong to?

The PTC Therapeutics sector is Healthcare.

PTC Therapeutics PTCT included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD